|
Gender (% male)
|
31% (12)
|
|
Known CAD
|
56% (22)
|
|
Pulmonary Hypertension
|
51% (20)
|
|
Atherosclerosis Risk Factors
|
|
Tobacco Use (prior or current)
|
46% (18)
|
|
Hypertension
|
67% (26)
|
|
Hyperlipidemia
|
54% (21)
|
|
Diabetes mellitus
|
18% (7)
|
|
Medication Regimen
|
|
ACE Inhibitors or ARB
|
51% (20)
|
|
Beta-Blockers
|
72% (28)
|
|
Aspirin
|
74% (29)
|
|
Statin
|
69% (27)
|
|
Diuretic
|
46% (18)
|
|
Cardiac Structure/Function
|
|
LVEF (%)
|
49 ± 14%
|
|
LV Dysfunction (EF < 50%)
|
49% (19)
|
|
LV End-Diastolic Volume
|
186 ± 57 ml
|
|
LV End-Systolic Volume
|
106 ± 56 ml
|
|
RV EF (%)
|
51 ± 11%
|
|
RV Dysfunction (EF < 50%)
|
31% (12)
|
|
RV End-Diastolic Volume
|
169 ± 62 ml
|
|
RV End-Systolic Volume
|
96 ± 52 ml
|
